Stockscreener 앱 받기
1.37
9.27%
-0.14
시간 외 거래:
1.40
0.03
+2.19%
전일 마감가:
$1.51
열려 있는:
$1.5
하루 거래량:
2.07M
Relative Volume:
0.51
시가총액:
$113.68M
수익:
$78.12M
순이익/손실:
$-153.22M
주가수익비율:
-0.6683
EPS:
-2.05
순현금흐름:
$-136.90M
1주 성능:
-23.03%
1개월 성능:
+11.38%
6개월 성능:
-65.32%
1년 성능:
-84.05%
1일 변동 폭
$1.36
$1.56
1주일 범위
$1.36
$1.829
52주 변동 폭
$1.12
$8.585
Editas Medicine Inc Stock (EDIT) Company Profile
명칭
Editas Medicine Inc
전화
617-401-9000
주소
11 HURLEY ST., CAMBRIDGE, MA
EDIT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.37 | 113.68M | 78.12M | -153.22M | -136.90M | -2.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-16 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-13 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-11 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-11-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-11-04 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-05-09 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-10-18 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-10-17 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | 업그레이드 | Stifel | Hold → Buy |
| 2023-06-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-13 | 개시 | Citigroup | Neutral |
| 2022-12-06 | 재개 | Credit Suisse | Neutral |
| 2022-11-18 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-09-29 | 개시 | BofA Securities | Neutral |
| 2021-10-19 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-09-10 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-08-09 | 업그레이드 | Truist | Hold → Buy |
| 2021-08-05 | 업그레이드 | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-04 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | 개시 | Goldman | Sell |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-01 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2021-02-26 | 다운그레이드 | Truist | Buy → Hold |
| 2021-01-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | 개시 | Robert W. Baird | Underperform |
| 2020-06-18 | 재개 | SunTrust | Buy |
| 2020-02-21 | 개시 | Wells Fargo | Equal Weight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-10-10 | 개시 | Guggenheim | Neutral |
| 2018-09-21 | 개시 | Raymond James | Outperform |
| 2018-05-15 | 재확인 | Chardan Capital Markets | Buy |
| 2018-02-13 | 개시 | CLSA | Underperform |
| 2018-01-23 | 업그레이드 | SunTrust | Hold → Buy |
| 2017-07-14 | 개시 | SunTrust | Hold |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2016-06-02 | 개시 | Jefferies | Hold |
| 2016-02-29 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-29 | 개시 | JP Morgan | Neutral |
| 2016-02-29 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine Reports Progress in Gene Editing - TipRanks
Gene Editing Market Future Business Opportunities 2025-2032 | - openPR
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely - Yahoo Finance
Editas Medicine’s SWOT analysis: gene editing firm pivots strategy amid stock volatility - Investing.com
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of “Hold” by Analysts - Defense World
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Editas Medicine Inc.’s Stock Volatility: Key Risks and Investor Considerations - TipRanks
Editas Medicine at Leerink’s Global Healthcare Conference: In Vivo Focus By Investing.com - Investing.com Canada
Editas Medicine (NASDAQ:EDIT) Issues Earnings Results - MarketBeat
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Editas Medicine (NASDAQ:EDIT) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS - MarketBeat
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures - TipRanks
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position - TipRanks
Editas Medicine, Inc. to Host Earnings Call - ACCESS Newswire
Editas Medicine (EDIT) Stock Price, News & Analysis - MarketBeat
Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight - GlobeNewswire Inc.
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas: Q4 Earnings Snapshot - Midland Daily News
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates - GlobeNewswire
Editas Medicine Inc reports results for the quarter ended December 31Earnings Summary - TradingView
EDITAS MEDICINE Earnings Results: $EDIT Reports Quarterly Earnings - Nasdaq
Editas Medicine Inc Reports Q4 2024 Loss of $0.55 EPS and $30.6 Million Revenue, Missing Estimates - GuruFocus.com
Editas Medicine shares fall as Q4 earnings miss estimates - Investing.com
EDITAS MEDICINE, INC. Q4 Loss Increases, Misses Estimates - Nasdaq
Editas Medicine reports Q4 EPS (55c), consensus (33c) - TipRanks
Can Editas Medicine's Strategic Shift to In Vivo Editing Reverse Its $237M Annual Loss? - StockTitan
Editas Medicine Q4 2024 Earnings Preview - MSN
Editas Medicine Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Top 5 CRISPR Companies To Invest In (March 2025) - Securities.io
Reviewing Aligos Therapeutics (NASDAQ:ALGS) & Editas Medicine (NASDAQ:EDIT) - Defense World
Editas Medicine Q1 2024 Earnings Preview - MSN
Editas Medicine (EDIT) Projected to Post Earnings on Wednesday - MarketBeat
Editas: The high-risk, high-reward gene editing pioneer - BioCentury
Peering Into Editas Medicine's Recent Short Interest - Benzinga
Editas Medicine to Announce Fourth Quarter/Full Year 2024 - GlobeNewswire
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March - The Manila Times
Editas Medicine to Announce Q4 2024 Financial Results and Upcoming Investor Conference Participation - Nasdaq
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate - The Bakersfield Californian
Access Editas Medicine's Full March Lineup: Earnings Plus 3 Major Healthcare Conferences - StockTitan
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $7.00 Average PT from Analysts - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 200-Day Moving AverageShould You Sell? - MarketBeat
Editas Medicine Inc (EDIT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):